» Articles » PMID: 35267511

Role of Furin in Colon Cancer Stem Cells Malignant Phenotype and Expression of LGR5 and NANOG in KRAS and BRAF-Mutated Colon Tumors

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 10
PMID 35267511
Authors
Affiliations
Soon will be listed here.
Abstract

Proprotein convertases or PCs are known to regulate the malignant phenotype of colon cancer cells by different mechanisms, but their effects on cancer stem cells (CSCs) have been less widely investigated. Here, we report that PCs expression is altered in colon CSCs, and the inhibition of their activity reduced colon CSCs growth, survival, and invasion in three-dimensional spheroid cultures. In vivo, repression of PCs activity by the general PC inhibitors α1-PDX, Spn4A, or decanoyl-RVKR-chloromethylketone (CMK) significantly reduced tumor expression levels of the stem cell markers LGR5 and NANOG that are associated with reduced tumor xenografts. Further analysis revealed that reduced tumor growth mediated by specific silencing of the convertase Furin in KRAS or BRAF mutated-induced colon tumors was associated with reduced expression of LGR5 and NANOG compared to wild-type KRAS and BRAF tumors. Analysis of various calcium regulator molecules revealed that while the calcium-transporting ATPase 4 (ATP2B4) is downregulated in all the Furin-silenced colon cancer cells, the Ca-mobilizing P2Y receptors, was specifically repressed in BRAF mutated cells and ORAI1 and CACNA1H in KRAS mutated cells. Taken together, our findings indicate that PCs play an important role in the malignant phenotype of colon CSCs and stem cell markers' expression and highlight PCs repression, particularly of Furin, to target colon tumors with KRAS or BRAF mutation.

Citing Articles

The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses.

Tout I, Bougarn S, Toufiq M, Gopinath N, Hussein O, Sathappan A J Transl Med. 2025; 23(1):193.

PMID: 39962504 PMC: 11834280. DOI: 10.1186/s12967-025-06176-0.


Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancer.

Demoures B, Soulet F, Descarpentrie J, Galeano-Otero I, Sanchez Collado J, Casado M EMBO Mol Med. 2025; 17(3):504-534.

PMID: 39962271 PMC: 11904221. DOI: 10.1038/s44321-025-00196-5.


Suppression of Metastasis of Colon Cancer to Liver in Mouse Models by Pretreatment with Extracellular Vesicles Derived from -Overexpressing Colon-26 Cancer Cells.

Henmi T, Matsuoka H, Katayama N, Saito M Int J Mol Sci. 2024; 25(23).

PMID: 39684502 PMC: 11640802. DOI: 10.3390/ijms252312794.


Is diabetes a real susceptibility for SARS-CoV-2 oral manifestation?.

Smitha T, Thomas A J Oral Maxillofac Pathol. 2024; 27(4):715-719.

PMID: 38304492 PMC: 10829469. DOI: 10.4103/jomfp.jomfp_208_23.


Multifaceted Insights into Innovative Approaches to Treating Colorectal Cancer Metastasis: From Emerging Biological Factors to Radiomics.

Ottaiano A, Circelli L, Santorsola M, Caraglia M Cancers (Basel). 2023; 15(18).

PMID: 37760613 PMC: 10526760. DOI: 10.3390/cancers15184644.


References
1.
Lin T, Ding Y, Li J . Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol. 2011; 29(2):878-85. DOI: 10.1007/s12032-011-9860-9. View

2.
Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

3.
Ibarrola-Villava M, Cervantes A, Bardelli A . Preclinical models for precision oncology. Biochim Biophys Acta Rev Cancer. 2018; 1870(2):239-246. DOI: 10.1016/j.bbcan.2018.06.004. View

4.
Schepers A, Snippert H, Stange D, van den Born M, van Es J, van de Wetering M . Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012; 337(6095):730-5. DOI: 10.1126/science.1224676. View

5.
Soulet F, Bodineau C, Hooks K, Descarpentrie J, Alves I, Dubreuil M . ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activation. JCI Insight. 2020; 5(14). PMC: 7453911. DOI: 10.1172/jci.insight.129070. View